Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | AML post-transplant maintenance: enasidenib & ivosidenib

Amir Fathi • 24 Nov 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Enasidenib Ivosidenib

Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA outlines the findings of two dose-escalation and expansion studies. One of the trials investigated the use of the IDH1 inhibitor ivosidenib in IDH1-mutated acute myeloid leukemia (AML) patients. The other looked at the use of enasidenib (ENA) in IDH2-mutated AML. Both trials investigate these regimens in the post-transplant maintenance setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Amir Fathi

1:17
Venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with AML
Amir Fathi • 21 Nov 2023
2:04
Hot topics in the AML space: menin inhibitors
Amir Fathi • 21 Nov 2023
1:44
Improving maintenance therapy in AML: exploring the role of IDH inhibitors
Amir Fathi • 21 Nov 2023
1:12
Managing adverse risk AML: clinical considerations & future outlooks
Amir Fathi • 21 Nov 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals